Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2010

TAP and Centre for Innovative Manufacturing in Regenerative Medicine Ink Five-Year Extension

  • The Automation Partnership is to continue its collaboration with the Engineering and Physical Sciences Research Council’s Centre for Innovative Manufacturing in Regenerative Medicine for a second five-year stretch. The focus is on innovative manufacturing in regenerative medicine.

    The new five-year partnership will allow further development and testing of TAP’s CompacT CellBase™ system for culturing clinically applicable stem cells in a GMP environment. TAP says that the extra funding means that it can also start new research with the center to develop its microscale bioreactor, ambr™.

    Continuation of the organizations’ partnership follows the award of a £5.3 million U.K. Government grant to the center.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »